肖英红

研究方向

长期从事 RNA病毒（如肠道病毒、黄病毒及新冠病毒）的研究工作, 研究方向包括的RNA病毒致病性、遗传进化及复制的机制、新型抗病毒治疗手段、疫苗及佐剂的开发等。应用病毒学、分子生物学、细胞生物学、免疫学、组织学等多种手段,应用多种模型如：细胞模型、类器官、动物模型，以肠道病毒如脊髓灰质炎病毒（PV）、柯萨奇病毒（CVB3）、肠道病D68型（EV-D68）、   黄病毒如寨卡病毒（ZIKV）、呼吸道病毒如新冠病毒（SARS-CoV-2）鼻病毒及流感病毒为模型, 已取得系统性、 深入性的重要研究发现及原创性的成果。近几年来共发表SCI论文10篇, 其中重要研究成果, 以第一及共同第一作者发表在国际权威期刊Cell(2021), Nature   Communications(2017), Cell Host & Microbe(2016), 共同第一作发表在Cell Metabolism(2021),  Plos  Pathogens(2021)，Cell(2022), Nature Microbiology(2023)上, 参与发表Cell，PNAS,   Plos Pathogens(多篇), Cell   Reports Medicine, Journal of Biological Chemistry。论文被领域中具有高影响力的综述和书籍引用, 2018年来, 论文总引用率超过1000次(谷歌学者)。研究成果受到领域内的广泛关注与好评。申请人主持NIH(R41，Co-PI) 2项, 正在审批中的专利3项。在国际会议进行相关学术报告多次, 并为： Viruses, Vaccines, Antimicrobial Agents and   Chemotherapy, Epidemiology and Infection, Journal of Virology,   Communications Biology, Journal of Medical Sciences, Biomedicine &   Pharmacotherapy等专业期刊审稿30余篇。

教育及工作经历

2003.09-2007.07  黑龙江省齐齐哈尔大学生命科学与工程学院, 理学学士（生物技术专业）

2007.09-2012.06  东北师范大学生命科学学院, 理学博士 (硕博连读, 细胞生物学专业)

2012.06- 2017.06  加州大学旧金山分校医学院(UCSF), 微生物学与免疫学系, 博士后(Postdoc researcher)

2017.06-2023.12  加州大学旧金山分校医学院(UCSF), 微生物学与免疫学系,

先后任副研究员、研究员(Associate specialist, Specialist)

2024-            中国科学院武汉病毒研究所，研究员

近五年承担项目

1.2021-2023   美国卫生署NIH(NIAID, R41), Targeting CoVidD-19   with a Therapeutic Interfering Particle. 58万美元, 课题共同负责人（Co-PI）。

2.2020-2021 Neutralization antibody   test. 中和抗体的测试, Bill& Melinda Gates   foundation，主要参与人。

3.2018-2020, Tests of the effectiveness of two   commercial-quality drugs against five different viruses, open philanthropy   project, 88万美元, 主要参与(横向), 子课题负责人。

4.2017-2020, rTIPS:"Trojan-horse" Interference   Particles Against Pathogenic RNA Viruses, 美国国防部高级研究计划局DARPA, 300万美元, 主要参与,   子课题负责人。

5.2017-2020, Mechanism of poliovirus   replication(5R015-18), 美国卫生署NIH(NIAID, R01), 40万美元, 主要参与人。

6.2018-2020，Selective AAK1 and GAK Inhibitors   for Combating Dengue and Other Emerging Viral Infections. AWARD NUMBER:   W81XWH-16-1-0691.Sponsoring/Monitoring Agency name(s) and Address (ES): U.S.   Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012.DoD  NIAID and The Ford Foundation, 主要参与人。

近五年代表性论文

1.Xiao Y., Peter V Lidsky, Yuta Shirogane, Ranen Aviner, Chien-Ting Wu, Weiyi Li, Weihao Zheng, Dale Talbot, Adam Catching, Gilad Doitsh, Weiheng Su, Colby E Gekko, Arabinda Nayak, Joel D Ernst, Leonid Brodsky, Elia Brodsky, Elsa Rousseau, Sara Capponi, Simone Bianco, Robert Nakamura, Peter K Jackson, Judith Frydman, Raul Andino*. A defective viral genome strategy elicits broad protective immunity against respiratory viruses.Cell.(2021).Published: November 18,2021. DOI:https://doi.org/10.1016/j.cell.2021.11.023.

2.JunJiao Yang^#,Xiao Y.^#, Petr V. Lidsky^#, Chien-Ting Wu, Miguel Garcia-Knight, Chan-I Chung, Xiaoquan Li, Tsuguhisa Nakayama, Ivan T. Lee, Jayakar V. Nayak, Peter K. Jackson, Raul Andino*, Xiaokun Shu*. Fluorogenic reporter enables identification of compounds that inhibit SARS-CoV-2.Nature Microbiology.(2023).https://doi.org/10.1038/s41564-022-01288-5.  (^#共同第一作者，Co-first   author, contributed equally).

3.Maurico Aguilar, Patrick Dolan, Shuhei Taguwa, Xiao Y., Raul Andino, Judith Frydman*.High-resolution mapping reveals the mechanism and contribution of genome insertions and deletions to RNA virus evolution.PNAS.(2023).Proceedings of the National Academy of Sciences.DOI: 10.1073/pnas.2304667120

4.Ranen Aviner, Peter V. Lidsky, Xiao Y., Michel Tassetto, Damian Kim, Lichao Zhang, Patrick L. McAlpine, Joshua Elias, Judith Frydman*, Raul Andino* .SARS-CoV-2 Nsp1 cooperates with initiation factors EIF1 and 1A to selectively enhance translation of viral RNA.PLoS Pathogens.(2024).20(2):e1011535. DOI: 10.1371/journal.ppat.1011535.

5.Chien-Ting Wu^#, Petr V. Lidsky^#,Xiao Y.^#,Ran Cheng^#, Ivan T. Lee, Sizun Jiang, Tsuguhisa Nakayama, Wei He, Janos Demeter, Rachel E. Turn, Laura Rojas, Garry P. Nolan *, Carlos Milla*, Jayakar V. Nayak*, Raul Andino*, Peter K. Jackson*. SARS-CoV-2 replication in airway epithelia requires motile cilia and microvillar reprogramming. Cell.(2022).https://doi.org/10.1016/j.cell.2022.11.030. (^#共同第一作者，Co-first author, contributed equally).

6.Chien-Ting Wu^#, Petr V. Lidsky^#,Xiao Y.^#, Ivan T Lee, Ran Cheng^#, Tsuguhisa Nakayama^#, Sizun Jiang^#, Janos Demeter, Romina J Bevacqua, Charles A Chang, Robert L Whitener, Anna K Stalder, Bokai Zhu, Han Chen, Yury Goltsev, Alexandar Tzankov, Jayakar V Nayak, Garry P Nolan, Matthias S Matter, Raul Andino*, Peter K. Jackson*.Cell Metabolism. (2021). SARS-CoV-2 infects human pancreatic β-cells and elicits β-cell impairment.Cell Metabolism.(2021). 33,1565–1576, August 3,2021.https://doi.org/10.1016/j.cmet.2021.05.013. (^#共同第一作者，Co-first author, contributed equally).

7.Xiaoquan Li,^#Petr V. Lidsky,^#Xiao Y.^#, Chien-Ting Wu, Miguel Garcia-Knight, Junjiao Yang, Tsuguhisa Nakayama, Jayakar V Nayak, Peter K Jackson, Raul Andino* and Xiaokun Shu*.Plos Pathogens. (2021).Ethacridine inhibits SARS-CoV-2 by inactivating viral particles in cellular models. https://doi.org/10.1371/journal.ppat.1009898. ( ^#共同第一作者，Co-first author, contributed equally).

8.Tsuguhisa Nakayama; Ivan T Lee, Sizun Jiang, Matthias S Matter, Carol H Yan, Jonathan B Overdevest, Chien-Ting Wu, Yury Goltsev, Liang-Chun Shih, Chun-Kang Liao, Bokai Zhu, Yunhao Bai, Peter Lidsky,Xiao Y.,David Zarabanda, Angela Yang, Meena Easwaran, Christian M Schürch, Pauline Chu, Han Chen, Anna K Stalder, David R McIlwain, Nicole A Borchard, Phillip A Gall, Sachi S Dholakia, Wei Le, Le Xu, Chih-Jaan Tai, Te-Huei Yeh, Elizabeth Erickson-Direnzo, Jason M Duran, Kirsten D Mertz, Peter H Hwang, Jasmin D Haslbauer, Peter K Jackson, Thomas Menter, Raul Andino, Peter D Canoll, Adam   S DeConde, Zara M Patel, Alexandar Tzankov, Garry P Nolan*, Jayakar V Nayak*.Cell Reports Medicine.(2021).Determinants of SARS-CoV-2 entry and   replication in airway mucosal tissue and susceptibility in smokers.Cell Reports Medicine.  Published on September 28, 2021. DOI:https://doi.org/10.1016/j.xcrm.2021.100421.

9.Xianding Deng, Miguel A Garcia-Knight, Mir M Khalid, Venice Servellita, Candace Wang, Mary Kate Morris, Alicia Sotomayor-González, Dustin R Glasner, Kevin R Reyes, Amelia S Gliwa, Nikitha P Reddy, Claudia Sanchez San Martin, Scot Federman, Jing Cheng, Joanna Balcerek, Jordan Taylor, Jessica A Streithorst, Steve Miller, Bharath Sreekumar, Pei-Yi Chen, Ursula Schulze-Gahmen, Taha Y Taha, Jennifer M Hayashi, Camille R Simoneau, G Renuka Kumar, Sarah McMahon, Peter V Lidsky,Xiao Y., Peera Hemarajata, Nicole M Green, Alex Espinosa, Chantha Kath, Monica Haw, John Bell, Jill K Hacker, Carl Hanson, Debra A Wadford, Carlos Anaya, Donna Ferguson, Phillip A Frankino, Haridha Shivram, Liana F Lareau, Stacia K Wyman, Melanie Ott*, Raul Andino*, Charles Y. Chiu*. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant.Cell.(2021).https://doi.org/10.1016/j.cell.2021.04.025.  

10. Yuta Shirogane, Elsa Rousseau, Jakub Voznica,Xiao Y., Weiheng Su, Adam Catching, Zachary J Whitfield, Igor M Rouzine, Simone Bianco, Raul Andino *. Experimental and mathematical insights on the interactions between poliovirus and a defective interfering genome.Plos Pathogens.(2021).2021 Sep 27;17(9):e1009277.  doi:10.1371/journal.ppat.1009277.

11.Xiao Y.^#, Patrick Timothy Dolan^#, Elizabeth Faul Goldstein, Min Li, Mikhail Farkov, Leonid Brodsky, Raul Andino*Nature communications. (2017). Poliovirus intra-host evolution is required to overcome tissue-specific innate immune responses.Nature communications.8, Article number: 375 (2017).

12.Xiao Y., Igor M Rouzine, Simone Bianco, Ashley Acevedo, Elizabeth Faul Goldstein, Mikhail Farkov, Leonid Brodsky,Raul Andino*.Cell host & microbe.(2016). RNA Recombination Enhances Adaptability and Is Required for Virus Spread and Virulence.Cell host & microbe.19(4), 493-503.

专利:  

1. 专利名称：Recombinant enteroviruses and uses thereof. eTIP1,专利申请号码：63047398,专利提交日期：07/02/2021， 美国专利局审批中, 排序（2/4）。

2. 专利名称：SARS-CoV-2 inactivation by ethacridine, 专利申请号码：63105846, 专利提交日期：10/26/2021，美国专利局审批中，排序（5/5）。

3. 专利名称：Perk activators as broad-spectrum antiviral drugs, 专利申请号码: 63324975，专利提交日期： 03/29/2022，美国专利局审批中，排序（2/4）。